CBD Stock Overview
Cannasouth Limited, a medicinal cannabis company, engages in the manufacture of cannabis-based ingredients and oral solutions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cannasouth Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$0.098 |
| 52 Week High | NZ$0.32 |
| 52 Week Low | NZ$0.096 |
| Beta | 0 |
| 1 Month Change | 2.08% |
| 3 Month Change | -6.67% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.33% |
Recent News & Updates
Shareholder Returns
| CBD | NZ Pharmaceuticals | NZ Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -1.1% |
| 1Y | n/a | 26.8% | -5.1% |
Return vs Industry: Insufficient data to determine how CBD performed against the NZ Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CBD performed against the NZ Market.
Price Volatility
| CBD volatility | |
|---|---|
| CBD Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in NZ Market | 7.5% |
| 10% least volatile stocks in NZ Market | 2.4% |
Stable Share Price: CBD's share price has been volatile over the past 3 months.
Volatility Over Time: CBD's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of NZ stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Mark Lucas | www.cannasouth.co.nz |
Cannasouth Limited, a medicinal cannabis company, engages in the manufacture of cannabis-based ingredients and oral solutions. It produces medicinal cannabis products and cannabinoid-based medicines to treat and support the health of patients with certain conditions. It also exports its products.
Cannasouth Limited Fundamentals Summary
| CBD fundamental statistics | |
|---|---|
| Market cap | NZ$32.39m |
| Earnings (TTM) | -NZ$8.81m |
| Revenue (TTM) | NZ$955.55k |
33.9x
P/S Ratio-3.7x
P/E RatioIs CBD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBD income statement (TTM) | |
|---|---|
| Revenue | NZ$955.55k |
| Cost of Revenue | NZ$2.18m |
| Gross Profit | -NZ$1.22m |
| Other Expenses | NZ$7.59m |
| Earnings | -NZ$8.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.027 |
| Gross Margin | -127.65% |
| Net Profit Margin | -921.78% |
| Debt/Equity Ratio | 5.9% |
How did CBD perform over the long term?
See historical performance and comparison